Heart study tests Lower-Dose blood thinner and new stents for better safety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be ≥ 18 years * Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. * Subject must have a culprit lesion in a native coronary artery with significant stenosis (\>50% by visual estimate) eligible for stent implantation * Subject must have clinical diagnosis of acute coronary syndrome Exclusion Criteria: * Following patients will be enrolled in stent comparison, but excluded from antiplatelet comparison. They will be classified as observational cohort. * Subjects ≥75 years * Body weight \<60 kg * History of TIA or stroke * The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Biolimus, Everolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.) * Patients with active pathologic bleeding * Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months. * Systemic (intravenous) Biolimus, or everolimus use within 12 months. * Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study. * History of bleeding diathesis, known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).